Compare DuPont de Nemours Inc (DD) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DuPont de Nemours Inc vs Zoetis Inc — how do they compare? DuPont de Nemours Inc trades at $144.26 (market cap $19.51B), while Zoetis Inc trades at $73.66 (market cap $31.14B). The key difference: Zoetis Inc is the larger of the two by market cap, and Zoetis Inc pays the higher dividend (2.81%). Which is the better fit depends on your goals.
| DD | ZTS | |
|---|---|---|
Market Cap | $19.51B | $31.14B |
Sector | Basic Materials | Health |
52-Week High | $154.59 | $156.76 |
52-Week Low | $90.24 | $71.91 |
Enterprise Value | $20.90B | $38.70B |
Dividend Yield | 1.66% | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DuPont (DD) trades at $144.65, up 2.18% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $232.80. Recent Q2 2026 earnings beat expectations with EPS of $1.88 versus $1.76 expected, driven by healthcare and industrial water demand, leading to a raised full-year 2026 outlook. The company announced strategic wins, including a membrane bioreactor system in Australia and an R&D 100 Award, highlighting innovation strength.
The stock presents growth potential from operational improvements and end-market recovery, but risks include a high P/E ratio of 62.01, net income margin of only 0.79%, and legal settlements over PFAS chemicals. Investor sentiment is positive due to earnings beats and raised guidance, though valuation concerns and liability exposures warrant caution for long-term holders.
Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.
The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DuPont de Nemours Inc
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
